

IFW

CASE PH 7483 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Debra A. Wojcik

Type or print name

a. W.

6-9-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

LEE ET AL.

APPLICATION NO: 10/743,449 FILED: DECEMBER 19, 2003

FOR: SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS

SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS

Mail Stop **Box Amendment** Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-6270

Date: 6/8/04

Sammy G. Duncan Jr. Ph.D. Attorney for Applicants

Reg. No. 46,675

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE .. PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

Ose several sheets if necessary)

ATTY. DOCKET NO. PH 7483 NP APPLICATION NO. 10/743,449 APPLICANT LEE ET AL. **FILING DATE DECEMBER 19, 2003**

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	3,914,421	10/21/75	Rajagopalan			
	AB	4,013,652	3/22/77	Rajagopalan			
	AC	4,115,577	9/19/78	Rajagopalan			
	AD	4,183,936	1/15/80	Rajagopalan			ē
<u>-</u>	AE	-4,219,550	8/26/80	Rajagopalan			
	AF	4,238,607	12/9/80	Rajagopalan			
	AG	6,548,493	4/15/03	Robichaud et al.			
	АН	6,552,017	4/22/03	Robichaud et al.			
	ΑI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
AM	EP 0 473 550	3/4/92	EP				
 AN	WO 00/35922	6/22/00	PCT				
 AO	WO 00/77001	12/21/00	PCT				
AP	WO 00/77002	12/21/00	PCT				
AQ	WO 00/77010	12/21/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Chojnacka-Wójcik, E. et al., "Involvement of 5-HT₂c Receptors in the m-CPP-Induced Antinociception in Mice", Pol. J. Pharmacol., Vol. 46, pp. 423-428 (1994)
AS	Cryan, J.F. et al., "Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine _{2C} Receptors", The Journal of Pharmacology and Experimental Therapeutics, Vol. 295, No. 3, pp. 1120-1126 (2000)
АТ	Grottick, A.J. et al., "Activation of 5-HT _{2C} receptors reduces the locomotor and rewarding effects of nicotine", Psychopharmacology, Vol. 157, pp. 292-298 (2001)

EXAMINER

DATE CONSIDERED

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PH 7483 NP APPLICATION NO. 10/743,449 APPLICANT LEE ET AL. FILING DATE DECEMBER 19, 2003

Group

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE OFFICE	OFFICE	CLASS	SUBCLAS	TRANSLATION	
<u> </u>						<u>s</u>	YES	NO
	2AA	WO 02/059129	8/1/02	PCT				
*	2AB	WO 03/014118	2/20/03	PCT				
	AC					···.		
	AD							
	AE							
	AF							
	AG							
	AH							
	Al					•		
	AJ							
	AK							
	AL							
	AM							
	AN							
	AO							
	AP							
	AQ							
	AR					(4)		
	AS							
	AT		 	•				
	AU							
	AV	-	<u> </u>					
	AW							
	AX							
	AY			 				一
	AZ				- 		計	一
FΧΔΙ	MINER	1.	1	DATE CONSIDERED				1

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE . PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PH 7483 NP **APPLICATION NO.** 10/743,449 APPLICANT LEE ET AL. FILING DATE **DECEMBER 19, 2003**

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

EXAMINER	DATE CONSIDERED
3AN	Vickers, S.P. et al., "Reduced satiating effect of <i>d</i> -fenfluramine in serotonin 5-HT _{2C} receptor mutant mice", Psychopharmacology, Vol. 143, pp. 309-314 (1999)
3AM	Vickers, S.P. et al., "Evidence that hypophagia induced by <i>d</i> -fenfluramine and <i>d</i> -norfenfluramine in the rat is mediated by 5-HT _{2C} receptors", Neuropharmacology, Vol. 41, pp. 200-209 (2001)
3AL	Vickers, S.P. et al., "Comparative effects of continuous infusion of <i>m</i> CPP, Ro 60-0175 and <i>d</i> -fenfluramine on food intake, water intake, body weight and locomotor activity in rats", British Journal of Pharmacology, Vol. 130, pp. 1305-1314 (2000)
зак	Tomori, H. et al., "Facile Optical Resolution of a Dibenzopyrazinoazepine Derivative and the Nature of Molecular Recognition of Amines by Chiral 2,3-Di-O-(arylcarbonyl)tartaric Acids", Bull. Chem. Soc. Jpn., Vol. 69, No. 12, pp. 3581-3590 (1996)
3AJ	Sundberg, R.J., Indoles, Academic Press Limited, publ., p. v (table of contents) (1996)
3AI	Sharpley, A.L. et al., "Slow Wave Sleep in Humans: Role of 5-HT _{2A} and 5-HT _{2C} Receptors", Neuropharmacology, Vol. 33, No. 3/4, pp. 467-471 (1994)
· 3AH	Rittenhouse, P.A. et al., "Evidence that ACTH Secretion Is Regulated by Serotonin _{2A/2C} (5-HT _{2A/2C}) Receptors", The Journal of Pharmacology and Experimental Therapeutics, Vol. 271, No. 3, pp. 1647-1655 (1994)
3AG	Nonogaki, K. et al., "Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT _{2C} receptor gene", Nature Medicine, Vol. 4, No. 10, pp. 1152-1156 (1998)
3AF	Millan, M.J. et al., "5-HT _{2C} receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists", European Journal of Pharmacology, Vol. 325, pp. 9-12 (1997)
3AE	Mazzola-Pomietto, P. et al., "Evidence that <i>m</i> -chlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT _{2C} receptors", Psychopharmacology, Vol. 123, pp. 333-339 (1996)
3AD	Kinbara, K. et al., "Chiral discrimination upon crystallization of the diastereomeric salts of 1-arylethylamines with mandelic acid or <i>p</i> -methoxymandelic acid: interpretation of the resolution efficiencies on the basis of the crystal structures", J. Chem. Soc., Perkin Trans. 2, pp. 2615-2622 (1996)
. 3AC	Hoyer, D. et al., "VII. International Union of Pharmacology Classification of Receptors for 5- Hydroxytryptamine (Serotonin)", Pharmacological Reviews, Vol. 46, No. 2, pp. 157-203 (1994)
3AB	Hoffman, B.J. et al., "Distribution of serotonin 5-HT _{1C} receptor mRNA in adult rat brain", FEBS Letters, Vol. 247, No. 2, pp. 453-462 (1989)
3AA	Grottick, A.J. et al., "Studies to Investigate the Role of 5-HT _{2C} Receptors on Cocaine- and Food-Maintained Behavior", The Journal of Pharmacology and Experimental Therapeutics, Vol. 293, No. 3, pp. 1183-1191 (2000)

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.